Literature DB >> 7744156

Treatment of sarcomatoid renal cell carcinoma: is there a role for chemotherapy?

S Culine1, M Bekradda, M J Terrier-Lacombe, J P Droz.   

Abstract

The sarcomatoid variant of renal cell carcinoma is a clinical entity with local and metastatic aggressiveness which translates to short survival time. Fourteen cases of patients that fit strict criteria for sarcomatoid cell carcinoma and convenient clinical data for treatment and follow-up were retrospectively selected among 1,235 patients treated at the Institut Gustave-Roussy over a 17-year period. Thirteen patients underwent initial nephrectomy. Local recurrence or distant metastases occurred in all patients. Only 1 patient was treated by surgical removal of a unique lung metastasis and is currently alive with no evidence of disease. No response was observed in all 4 patients treated with alpha-interferon. Chemotherapy was administered in 10 patients, 8 of whom received doxorubicin-based regimens. The survival was 20, 29 and 60 months for the 3 responding patients as compared to a median of 9 months for patients with progressive disease. Further phase II studies are warranted to define the real impact of chemotherapy in this disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7744156     DOI: 10.1159/000475145

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  9 in total

1.  Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease.

Authors:  Ana M Molina; Satish K Tickoo; Nicole Ishill; Michael J Trinos; Lawrence H Schwartz; Sujata Patil; Darren R Feldman; Victor E Reuter; Paul Russo; Robert J Motzer
Journal:  Am J Clin Oncol       Date:  2011-10       Impact factor: 2.339

Review 2.  Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art.

Authors:  Cedric Lebacle; Aydin Pooli; Thomas Bessede; Jacques Irani; Allan J Pantuck; Alexandra Drakaki
Journal:  World J Urol       Date:  2018-06-01       Impact factor: 4.226

3.  Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma.

Authors:  Abhishek Maiti; Maryam Nemati-Shafaee; Pavlos Msaouel; Lance C Pagliaro; Eric Jonasch; Nizar M Tannir; Amishi Y Shah
Journal:  Clin Genitourin Cancer       Date:  2017-08-10       Impact factor: 2.872

Review 4.  Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies.

Authors:  Brian Shuch; Gennady Bratslavsky; W Marston Linehan; Ramaprasad Srinivasan
Journal:  Oncologist       Date:  2012-01-10

5.  Does postoperative radiation therapy impact survival in non-metastatic sarcomatoid renal cell carcinoma? A SEER-based study.

Authors:  Okyaz Eminaga; Ilgar Akbarov; Sebastian Wille; Udo Engelmann
Journal:  Int Urol Nephrol       Date:  2015-09-02       Impact factor: 2.370

6.  Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component.

Authors:  Inkeun Park; Yong Mee Cho; Jae-Lyun Lee; Jin-Hee Ahn; Dae-Ho Lee; Cheryn Song; Jun-Hyuk Hong; Choung-Soo Kim; Hanjong Ahn
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-09       Impact factor: 4.553

7.  Sarcomatoid Renal Cell Carcinoma With Unusual Metastasis to the Small Intestine Manifesting as Perforated Appendicitis.

Authors:  Xiaoyan Liao; Sohaib H Abu-Farsakh; Dongwei Zhang
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

8.  Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation.

Authors:  Michael Staehler; N Haseke; A Roosen; T Stadler; M Bader; M Siebels; A Karl; C G Stief
Journal:  Eur J Med Res       Date:  2010       Impact factor: 2.175

Review 9.  Sarcomatoid renal cell carcinoma: biology, natural history and management.

Authors:  Jose A Karam; A Ari Hakimi; Kyle A Blum; Sounak Gupta; Satish K Tickoo; Timothy A Chan; Paul Russo; Robert J Motzer
Journal:  Nat Rev Urol       Date:  2020-10-13       Impact factor: 14.432

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.